|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chou HC and Chan HL: Effect of glutathione
reductase knockdown in response to UVB-induced oxidative stress in
human lung adenocarcinoma. Proteome Sci. 12:22014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pilotto S, Bria E, Peretti U, Massari F,
Garassino M, Pelosi G and Tortora G: Lung adenocarcinoma patient
refractory to gefitinib and responsive to crizotinib, with
concurrent rare mutation of the epidermal growth factor receptor
(L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac
Oncol. 8:e105–e106. 2013. View Article : Google Scholar
|
|
4
|
Onn A, Tsuboi M and Thatcher N: Treatment
of non-small-cell lung cancer: A perspective on the recent advances
and the experience with gefitinib. Br J Cancer. 91(Suppl 2):
S11–S17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang W, Zhang J, Liang W, Huang Y, Yan Y,
Wu X, Hu Z, Ma Y, Zhao H, Zhao Y, et al: Efficacy of epidermal
growth factor receptor-tyrosine kinase inhibitors for Chinese
patients with squamous cell carcinoma of lung harboring EGFR
mutation. J Thorac Dis. 5:585–592. 2013.PubMed/NCBI
|
|
6
|
Shimada Y, Saji H, Nomura M, Matsubayashi
J, Yoshida K, Kakihana M, Kajiwara N, Ohira T and Ikeda N: Cancer
stem cell-related marker expression in lung adenocarcinoma and
relevance of histologic subtypes based on IASLC/ATS/ERS
classification. Onco Targets Ther. 6:1597–1604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dar AA, Goff LW, Majid S, Berlin J and
El-Rifai W: Aurora kinase inhibitors - rising stars in cancer
therapeutics? Mol Cancer Ther. 9:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kallioniemi A, Kallioniemi OP, Piper J,
Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman
FM: Detection and mapping of amplified DNA sequences in breast
cancer by comparative genomic hybridization. Proc Natl Acad Sci
USA. 91:2156–2160. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Romain C, Paul P, Kim KW, Lee S, Qiao J
and Chung DH: Targeting Aurora kinase-A downregulates cell
proliferation and angiogenesis in neuroblastoma. J Pediatr Surg.
49:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thrane S, Pedersen AM, Thomsen MB,
Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M,
Lykkesfeldt AE and Yde CW: A kinase inhibitor screen identifies
Mcl-1 and Aurora kinase A as novel treatment targets in
anti-estrogen-resistant breast cancer cells. Oncogene.
34:4199–4210. 2015. View Article : Google Scholar
|
|
11
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shedden K, Taylor JM, Enkemann SA, Tsao
MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ,
Misek DE, et al; Director’s Challenge Consortium for the Molecular
Classification of Lung Adenocarcinoma. Gene expression-based
survival prediction in lung adenocarcinoma: A multi-site, blinded
validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zielske SP and Stevenson M: Importin 7 may
be dispensable for human immunodeficiency virus type 1 and simian
immunodeficiency virus infection of primary macrophages. J Virol.
79:11541–11546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeng YM, Peng SY, Lin CY and Hsu HC:
Overexpression and amplification of Aurora-A in hepatocellular
carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong Q, Meng P, Wang T, Qin W, Qin W, Wang
F, Yuan J, Chen Z, Yang A and Wang H: MicroRNA let-7a inhibits
proliferation of human prostate cancer cells in vitro and in vivo
by targeting E2F2 and CCND2. PLoS One. 5:e101472010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mermelshtein A, Gerson A, Walfisch S,
Delgado B, Shechter-Maor G, Delgado J, Fich A and Gheber L:
Expression of D-type cyclins in colon cancer and in cell lines from
colon carcinomas. Br J Cancer. 93:338–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Susaki E, Nakayama K and Nakayama KI:
Cyclin D2 translocates p27 out of the nucleus and promotes its
degradation at the G0–G1 transition. Mol Cell Biol. 27:4626–4640.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hedberg Y, Roos G, Ljungberg B and
Landberg G: Cyclin D3 protein content in human renal cell carcinoma
in relation to cyclin D1 and clinico-pathological parameters. Acta
Oncol. 41:175–181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ito Y, Takeda T, Wakasa K, Tsujimoto M and
Matsuura N: Expression and possible role of cyclin D3 in human
pancreatic adenocarcinoma. Anticancer Res. 21:1043–1048.
2001.PubMed/NCBI
|
|
22
|
Wong SC, Chan JK, Lee KC and Hsiao WL:
Differential expression of p16/p21/p27 and cyclin D1/D3, and their
relationships to cell proliferation, apoptosis, and tumour
progression in invasive ductal carcinoma of the breast. J Pathol.
194:35–42. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Retzer-Lidl M, Schmid RM and Schneider G:
Inhibition of CDK4 impairs proliferation of pancreatic cancer cells
and sensitizes towards TRAIL-induced apoptosis via downregulation
of survivin. Int J Cancer. 121:66–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karim BO, Rhee KJ, Liu G, Zheng D and Huso
DL: Chemoprevention utility of silibinin and Cdk4 pathway
inhibition in Apc(−/+) mice. BMC Cancer. 13:1572013. View Article : Google Scholar
|
|
25
|
Chan KC, Ting CM, Chan PS, Lo MC, Lo KW,
Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, et al: A novel Hsp90
inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal
carcinoma cells and suppresses tumor formation. Mol Cancer.
12:1282013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Poomsawat S, Buajeeb W, Khovidhunkit SO
and Punyasingh J: Alteration in the expression of cdk4 and cdk6
proteins in oral cancer and premalignant lesions. J Oral Pathol
Med. 39:793–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang LH, Contractor T, Clausen R, Klimstra
DS, Du YC, Allen PJ, Brennan MF, Levine AJ and Harris CR:
Attenuation of the retinoblastoma pathway in pancreatic
neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res.
18:4612–4620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu A, Wu B, Guo J, Luo W, Wu D, Yang H,
Zhen Y, Yu X, Wang H, Zhou Y, et al: Elevated expression of CDK4 in
lung cancer. J Transl Med. 9:382011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sørensen CS and Syljuåsen RG: Safeguarding
genome integrity: The checkpoint kinases ATR, CHK1 and WEE1
restrain CDK activity during normal DNA replication. Nucleic Acids
Res. 40:477–486. 2012. View Article : Google Scholar :
|
|
30
|
Callow MG, Clairvoyant F, Zhu S, Schryver
B, Whyte DB, Bischoff JR, Jallal B and Smeal T: Requirement for
PAK4 in the anchorage-independent growth of human cancer cell
lines. J Biol Chem. 277:550–558. 2002. View Article : Google Scholar
|
|
31
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak
VC, Ngan HY, Wong OG, Zhang HQ and Cheung AN: Overexpressed PAK4
promotes proliferation, migration and invasion of choriocarcinoma.
Carcinogenesis. 32:765–771. 2011.PubMed/NCBI
|
|
33
|
Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X,
Lee HJ, Suh N, Yang CS and Minden A: The pak4 protein kinase plays
a key role in cell survival and tumorigenesis in athymic mice. Mol
Cancer Res. 6:1215–1224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kimmelman AC, Hezel AF, Aguirre AJ, Zheng
H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, et al:
Genomic alterations link Rho family of GTPases to the highly
invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA.
105:19372–19377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar
|
|
36
|
Cheng L, Zhang S, Alexander R, Yao Y,
MacLennan GT, Pan CX, Huang J, Wang M, Montironi R and
Lopez-Beltran A: The landscape of EGFR pathways and personalized
management of non-small-cell lung cancer. Future Oncol. 7:519–541.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamamoto H, Toyooka S and Mitsudomi T:
Impact of EGFR mutation analysis in non-small cell lung cancer.
Lung Cancer. 63:315–321. 2009. View Article : Google Scholar
|
|
39
|
Inamura K, Ninomiya H, Ishikawa Y and
Matsubara O: Is the epidermal growth factor receptor status in lung
cancers reflected in clinicopathologic features? Arch Pathol Lab
Med. 134:66–72. 2010.PubMed/NCBI
|
|
40
|
Alejandro EU, Kalynyak TB, Taghizadeh F,
Gwiazda KS, Rawstron EK, Jacob KJ and Johnson JD: Acute insulin
signaling in pancreatic beta-cells is mediated by multiple Raf-1
dependent pathways. Endocrinology. 151:502–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang H, Gambosova K, Cooper ZA, Holloway
MP, Kassai A, Izquierdo D, Cleveland K, Boney CM and Altura RA: EGF
regulates survivin stability through the Raf-1/ERK pathway in
insulin-secreting pancreatic β-cells. BMC Mol Biol. 11:662010.
View Article : Google Scholar
|
|
42
|
Yoon S and Seger R: The extracellular
signal-regulated kinase: Multiple substrates regulate diverse
cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Magnussen GI, Holm R, Emilsen E, Rosnes
AK, Slipicevic A and Flørenes VA: High expression of Wee1 is
associated with poor disease-free survival in malignant melanoma:
Potential for targeted therapy. PLoS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Murrow LM, Garimella SV, Jones TL, Caplen
NJ and Lipkowitz S: Identification of WEE1 as a potential molecular
target in cancer cells by RNAi screening of the human tyrosine
kinome. Breast Cancer Res Treat. 122:347–357. 2010. View Article : Google Scholar
|
|
45
|
Mir SE, De Witt Hamer PC, Krawczyk PM,
Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts
D, Kaspers GJ, et al: In silico analysis of kinase expression
identifies WEE1 as a gatekeeper against mitotic catastrophe in
glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
